Adrian G. Sacher

Dr. Adrian G. Sacher


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
ASAdrian G. Sacher
Adrian G. Sacher
CPCloud Paweletz
Cloud Paweletz
SDSuzanne E. Dahlberg
Suzanne E. Dahlberg
RARyan S. Alden
Ryan S. Alden
AFAllison Fitzgerald
Allison Fitzgerald
GOGeoffrey R. Oxnard
Geoffrey R. Oxnard
Plasma genotyping uses tumor-derived cell-free DNA (cfDNA) to allow for rapid noninvasive genotyping of tumors. This technology is currently poised to transition into a treatment decision-making tool in multiple cancer types. It is particularly relevant to the treatment of advanced non–small-cell lung cancer (NSCLC), in which therapy hinges on rapid and accurate detection of targetable epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS1 alterations.1-6 Plasma genotyping is capable of circumventing many limitations of standard tissue genotyping including slow turnaround time (TAT), limited tissue for testing, and the potential for failed biopsies. It may be particularly useful in directing the rapid use of new targeted therapies for acquired resistance in advanced EGFR-mutant NSCLC, where the need for a repeat biopsy to test for resistance mechanisms has amplified the inherent limitations of traditional genotyping.7,8

1 March 2016 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
ASAdrian G. Sacher
Adrian G. Sacher
SDSuzanne E. Dahlberg
Suzanne E. Dahlberg
JHJennifer Heng
Jennifer Heng
SMStacy Mach
Stacy Mach
PJPasi A. Jänne
Pasi A. Jänne
GOGeoffrey R. Oxnard
Geoffrey R. Oxnard
Non–small-cell lung cancer (NSCLC) is increasingly understood as a heterogeneous disease, both in its clinical presentation and its genomic make-up. While older age is a commonly considered factor in selecting treatment, younger age is a relatively minor factor when planning care or therapy for patients with NSCLC.1,2 This is in contrast to a number of cancers where young age at diagnosis is understood to represent a distinct disease biology. For instance, breast cancer occurring in young patients has been associated with both an increased frequency of BRCA1 and BRCA2 mutations, as well as an increased likelihood of ERBB2 overexpression and triple-negative disease.3-5 Breast cancer in younger patients has also been demonstrated to exhibit a more aggressive disease biology and has been associated with higher mortality even after controlling for the effect of genetics and therapy.6-8 Colon cancer in young patients has been associated with higher rates of microsatellite instability and similarly demonstrates more aggressive disease biology.9-12 Acute lymphoblastic leukemia in older adolescents and young adults exhibits a poorer prognosis than pediatric patients but better outcomes than older age groups and may benefit from more aggressive treatment regimens.13-17

14 February 2016 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CPCloud P. Paweletz
Cloud P. Paweletz
ASAdrian G. Sacher
Adrian G. Sacher
CRChris K. Raymond
Chris K. Raymond
RARyan S. Alden
Ryan S. Alden
AFAllison Fitzgerald
Allison Fitzgerald
GOGeoffrey R. Oxnard
Geoffrey R. Oxnard
Purpose: Tumor genotyping is a powerful tool for guiding non–small cell lung cancer (NSCLC) care; however, comprehensive tumor genotyping can be logistically cumbersome. To facilitate genotyping, we developed a next-generation sequencing (NGS) assay using a desktop sequencer to detect actionable mutations and rearrangements in cell-free plasma DNA (cfDNA). Experimental Design: An NGS panel was developed targeting 11 driver oncogenes found in NSCLC. Targeted NGS was performed using a novel methodology that maximizes on-target reads, and minimizes artifact, and was validated on DNA dilutions derived from cell lines. Plasma NGS was then blindly performed on 48 patients with advanced, progressive NSCLC and a known tumor genotype, and explored in two patients with incomplete tumor genotyping. Results: NGS could identify mutations present in DNA dilutions at ≥0.4% allelic frequency with 100% sensitivity/specificity. Plasma NGS detected a broad range of driver and resistance mutations, including ALK, ROS1, and RET rearrangements, HER2 insertions, and MET amplification, with 100% specificity. Sensitivity was 77% across 62 known driver and resistance mutations from the 48 cases; in 29 cases with common EGFR and KRAS mutations, sensitivity was similar to droplet digital PCR. In two cases with incomplete tumor genotyping, plasma NGS rapidly identified a novel EGFR exon 19 deletion and a missed case of MET amplification. Conclusions: Blinded to tumor genotype, this plasma NGS approach detected a broad range of targetable genomic alterations in NSCLC with no false positives including complex mutations like rearrangements and unexpected resistance mutations such as EGFR C797S. Through use of widely available vacutainers and a desktop sequencing platform, this assay has the potential to be implemented broadly for patient care and translational research. Clin Cancer Res; 22(4); 915–22. ©2015 AACR. See related commentary by Tsui and Berger, p. 790

4 April 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SPSumanta K Pal
Sumanta K Pal
BTBen Tran
Ben Tran
JHJohn B.A.G. Haanen
John B.A.G. Haanen
MHMichael E. Hurwitz
Michael E. Hurwitz
ASAdrian G. Sacher
Adrian G. Sacher
SSSamer A. Srour
Samer A. Srour
Therapeutic approaches for clear cell renal cell carcinoma (ccRCC) remain limited; however, chimeric antigen receptor (CAR) T-cell therapies may offer novel treatment options. CTX130, an allogeneic CD70-targeting CAR T-cell product, was developed for the treatment of advanced or refractory ccRCC. We report that CTX130 showed favorable preclinical proliferation and cytotoxicity profiles and completely regressed RCC xenograft tumors. We also report results from 16 patients with relapsed/refractory ccRCC who received CTX130 in a phase I, multicenter, first-in-human clinical trial. No patients encountered dose-limiting toxicity, and disease control was achieved in 81.3% of patients. One patient remains in a durable complete response at 3 years. Finally, we report on a next-generation CAR T construct, CTX131, in which synergistic potency edits to CTX130 confer improved expansion and efficacy in preclinical studies. These data represent a proof of concept for the treatment of ccRCC and other CD70+ malignancies with CD70− targeted allogeneic CAR T cells. Significance: Although the role of CAR T cells is well established in hematologic malignancies, the clinical experience in solid tumors has been disappointing. This clinical trial demonstrates the first complete response in a patient with RCC, reinforcing the potential benefit of CAR T cells in the treatment of solid tumors.

8 April 2007 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDPhedias Diamandis
Phedias Diamandis
JWJan Wildenhain
Jan Wildenhain
ICIan D Clarke
Ian D Clarke
ASAdrian G. Sacher
Adrian G. Sacher
JGJeremy Graham
Jeremy Graham
PDPeter B Dirks
Peter B Dirks

1 March 2013 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
ASAdrian G. Sacher
Adrian G. Sacher
LLLisa W. Le
Lisa W. Le
NLNatasha B. Leighl
Natasha B. Leighl
LCLinda E. Coate
Linda E. Coate